KR20040081165A - 펩타이드 항체 및 이를 이용한 아밀로이드-관련 질환의진단 및 치료 방법 - Google Patents

펩타이드 항체 및 이를 이용한 아밀로이드-관련 질환의진단 및 치료 방법 Download PDF

Info

Publication number
KR20040081165A
KR20040081165A KR10-2004-7011868A KR20047011868A KR20040081165A KR 20040081165 A KR20040081165 A KR 20040081165A KR 20047011868 A KR20047011868 A KR 20047011868A KR 20040081165 A KR20040081165 A KR 20040081165A
Authority
KR
South Korea
Prior art keywords
peptide
amino acid
group
pharmaceutical composition
seq
Prior art date
Application number
KR10-2004-7011868A
Other languages
English (en)
Korean (ko)
Inventor
휴드 가지트
Original Assignee
텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/235,852 external-priority patent/US20040052928A1/en
Application filed by 텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피. filed Critical 텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피.
Publication of KR20040081165A publication Critical patent/KR20040081165A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/585Calcitonins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0819Tripeptides with the first amino acid being acidic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1021Tetrapeptides with the first amino acid being acidic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR10-2004-7011868A 2002-01-31 2003-01-30 펩타이드 항체 및 이를 이용한 아밀로이드-관련 질환의진단 및 치료 방법 KR20040081165A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US35257802P 2002-01-31 2002-01-31
US60/352,578 2002-01-31
US39226602P 2002-07-01 2002-07-01
US60/392,266 2002-07-01
US10/235,852 US20040052928A1 (en) 2002-09-06 2002-09-06 Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US10/235,852 2002-09-06
US43645302P 2002-12-27 2002-12-27
US60/436,453 2002-12-27
PCT/IL2003/000079 WO2003063760A2 (en) 2002-01-31 2003-01-30 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases

Publications (1)

Publication Number Publication Date
KR20040081165A true KR20040081165A (ko) 2004-09-20

Family

ID=27671045

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7011868A KR20040081165A (ko) 2002-01-31 2003-01-30 펩타이드 항체 및 이를 이용한 아밀로이드-관련 질환의진단 및 치료 방법

Country Status (6)

Country Link
EP (1) EP1534310A4 (de)
JP (1) JP2006506942A (de)
KR (1) KR20040081165A (de)
AU (1) AU2003207973A1 (de)
CA (1) CA2473987C (de)
WO (1) WO2003063760A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180061982A (ko) * 2016-11-30 2018-06-08 연세대학교 산학협력단 세포 내부 pH 감응성 융합 펩티드 및 이를 유효성분으로 포함하는 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환을 예방 또는 치료하기 위한 약학 조성물

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
EP2058275A1 (de) 2003-01-07 2009-05-13 Ramot at Tel-Aviv University Ltd. Peptidnanostrukturen mit einem verkapselten Fremdstoff und Verfahren zu ihrer Herstellung
KR101215821B1 (ko) 2003-06-30 2012-12-28 텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피. 아밀로이드 관련 질환을 진단 및 처치하기 위한 펩타이드, 그것에 대한 항체, 및 그 사용방법
EP1781310B1 (de) 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Artikel von peptidnanostrukturen und herstellungsverfahren dafür
EP1973928A2 (de) 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Selbstzusammengebaute fmoc-ff-hydrogele
WO2007126111A1 (ja) 2006-04-28 2007-11-08 Kagoshima University アミロイドβ線維化阻害ペプチド
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
RU2013124827A (ru) * 2010-10-29 2014-12-10 Мерц Фарма Гмбх Унд Ко. Кгаа Производные индола и способ их получения
EP3431489B1 (de) 2010-11-15 2020-12-23 Ramot at Tel-Aviv University Ltd. Dipeptidanaloga zur behandlung von störungen im zusammenhang mit amyloid-fibrillen-bildung
EP2686313B1 (de) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazolderivate als glutaminylcyclase-hemmer
PL2895512T3 (pl) * 2012-09-12 2018-11-30 Neurimmune Holding Ag Przeciwciała swoiste dla polipeptydu amyloidowego ludzkich wysepek (HIAPP) i ich zastosowania
CA3072884A1 (en) * 2017-08-11 2019-02-14 University Of Kentucky Research Foundation Anti-neurodegenerative therapeutic, method of manufacture, and use
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
TW202144387A (zh) * 2020-02-11 2021-12-01 美商聯合生物醫學公司 針對胰島澱粉樣多肽(iapp)的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑
WO2024121156A1 (en) * 2022-12-05 2024-06-13 Neurimmune Ag Cyclic compounds and their use in assays for detecting antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6344895A (ja) * 1986-08-13 1988-02-25 Kyowa Hakko Kogyo Co Ltd 抗アミロイドa蛋白質単クロ−ン性抗体
AU7261994A (en) * 1993-07-19 1995-02-20 Resolution Pharmaceuticals Inc. Hydrazino-type radionuclide chelators having an n3s configuration
US6303567B1 (en) * 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
EP0941334B1 (de) * 1996-11-06 2004-06-02 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Protease-aktivierbare pseudomonas exotoxin-a-ähnliche proproteine
JP2000193661A (ja) * 1998-12-25 2000-07-14 Tokyo Rika Kikai Kk 痴呆症の検査方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180061982A (ko) * 2016-11-30 2018-06-08 연세대학교 산학협력단 세포 내부 pH 감응성 융합 펩티드 및 이를 유효성분으로 포함하는 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환을 예방 또는 치료하기 위한 약학 조성물

Also Published As

Publication number Publication date
JP2006506942A (ja) 2006-03-02
EP1534310A4 (de) 2006-05-31
WO2003063760A2 (en) 2003-08-07
EP1534310A2 (de) 2005-06-01
CA2473987C (en) 2013-11-19
WO2003063760A3 (en) 2005-02-10
CA2473987A1 (en) 2003-08-07
AU2003207973A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
EP2719394B1 (de) Peptide zur Behandlung von amyloidbedingten Erkrankungen
US8563273B2 (en) Method of screening for compounds that disaggregate amyloid aggregates
US8012929B2 (en) Peptides directed for diagnosis and treatment of amyloid-associated diseases
KR20040081165A (ko) 펩타이드 항체 및 이를 이용한 아밀로이드-관련 질환의진단 및 치료 방법
EP1765378B1 (de) Mittel zur down-regulierung eines msf-a-abhängigen hif-1a und seine verwendung bei der behandlung von krebs
US8349801B2 (en) Peptide ligands for G-protein coupled receptors
US20050020809A1 (en) Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US20160168212A1 (en) Compositions for treatment of neurodegenerative diseases
AU2004203461B2 (en) Peptides Antibodies Directed Thereagainst and Methods Using Same for Diagnosing and Treating Amyloid-Associated Diseases
IL210418A (en) Peptides for treating amyloid-associated diseases
IL172788A (en) Use of peptides in the manufacture of medicaments for treating amyloid-associated diseases

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E90F Notification of reason for final refusal
E601 Decision to refuse application